drugset / Trial / NCT00697931
Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study is to compare the immunogenicity and reactogenicity of the adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B when both are injected according to a three dose schedule (0, 1, 6 months) in an adult non-responder population
Timeline
- Start
- 1997-05
- Primary completion
- 1998-06
- Completion
- 1998-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | MPL-Adjuvanted Recombinant Hepatitis B Vaccine | Vaccine | — | Intramuscular |